Related Experiment Video

Updated: Aug 17, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Life with continuous subcutaneous insulin infusion (CSII) therapy: child and parental perspectives and predictors of

A K Maniatis1, S R Toig, G J Klingensmith

  • 1The Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Denver, 80262, USA.

Pediatric Diabetes
|March 16, 2004
PubMed

Insights

Needle fear in pediatric patients on continuous subcutaneous insulin infusion (CSII) therapy is linked to poorer metabolic control. Parental involvement and anxiety generally remained stable or decreased during CSII therapy.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Diabetes Management

Background:

  • Continuous subcutaneous insulin infusion (CSII) therapy is a common treatment for pediatric diabetes.
  • Evaluating CSII therapy's impact on metabolic control and parental factors is crucial for optimizing patient care.

Purpose of the Study:

  • To assess metabolic control in pediatric patients using CSII therapy.
  • To identify reasons for initiating CSII and daily management challenges, including needle fear.
  • To evaluate changes in parental involvement and anxiety after initiating CSII therapy.

Main Methods:

  • The study included 52 pediatric patients (aged 7.6-23.6 years) from a diabetes clinic.
  • Management issues analyzed included diet, exercise, home blood glucose monitoring (HBGM) frequency, and needle fear.
  • Metabolic control was assessed by HbA1c changes and final HbA1c levels.

Main Results:

  • Needle fear was present in over a quarter of subjects (26.9%) and predicted poorer metabolic control (p=0.03).
  • Most patients initiated CSII for better control, to avoid injections, and for flexibility.
  • Home blood glucose monitoring (HBGM) frequency increased significantly on CSII (p=0.02).

Conclusions:

  • Needle fear is a significant predictor of suboptimal metabolic control in pediatric CSII therapy.
  • CSII therapy did not lead to increased parental involvement or anxiety, even with poorer metabolic control.
Abstract

More Related Videos

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate05:58

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Published on: June 25, 2019

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...